Momenta Phamaceuticals (MNTA) Posts Surprise Q4 Loss; Guides OpEx
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Financial Fact:
Total collaboration revenue: 29.14M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Total collaboration revenue: 29.14M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Momenta Phamaceuticals, Inc. (NASDAQ: MNTA) reported Q4 EPS of ($0.02), $0.29 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $29.5 million versus the consensus estimate of $38.59 million.
Sees total operating expenses, excluding stock compensation and royalties payable to MIT, and net of collaborative revenues, increasing to approximately $22 to $28 million per quarter for 2012.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Sees total operating expenses, excluding stock compensation and royalties payable to MIT, and net of collaborative revenues, increasing to approximately $22 to $28 million per quarter for 2012.
For earnings history and earnings-related data on Momenta Phamaceuticals, Inc. (MNTA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
- Investing.com’s stocks of the week
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
